Q

QuidelOrtho

Develops, produces, and markets diagnostic tests

Marketing Manager - Automation

Full-Time
$117.7k - $155k/yr+ Bonus
Expert
Bachelor's
Remote in USA
HybridRemote role with up to 20% travel, including some overnight and global travel.
Growth & MarketingMarketing Generalist & Management

About the job

Requirements
  • A minimum of a Bachelor's Degree or 10 years of equivalent experience in Sales or Marketing within the industry.
  • A minimum of 10 years of healthcare or medical device experience in a commercial organization.
  • Strong leadership, interpersonal, and conceptual skills resulting from education and work experience.
  • Strong communication, presentation, and analytic skills.
  • Proven experience translating complex technology into simple marketing messages.
  • A highly professional demeanor.
  • Experience executing downstream product marketing strategy.
  • Experience managing key performance indicators and strategic imperatives.
  • Experience collaborating with field sales and customer-facing teams.
  • Experience supporting commercial organizations in achieving annual operating plan objectives.
  • Experience providing updates on the business, demand plan, and forecast.
Responsibilities
  • Develop and execute Automation marketing strategies, plans, and playbooks aligned with North America commercial objectives to drive revenue growth, customer retention, customer adoption, lead generation, system placements, and competitive differentiation.
  • Lead the development and execution of integrated marketing initiatives and campaigns that promote Automation and associated service offerings, increase brand awareness, drive customer engagement, and support pipeline growth and funnel conversion.
  • Develop and maintain customer-facing and internal value propositions, positioning, messaging, collateral, and promotional tools to ensure consistent, differentiated communication and effective commercialization of Automation solutions.
  • Partner with Sales, Field Service, Learning and Development, and Business Unit and Channel Marketing to support customer acquisition, implementation, onboarding, training, and customer success while ensuring commercial teams achieve required product knowledge and capability levels.
  • Identify customer segments, unmet needs, market opportunities, competitive threats, and emerging healthcare trends through market research, Voice of Customer, customer engagement, and business analysis to inform growth strategies, product development priorities, and business case development.
  • Collaborate across regional and global cross-functional teams to align strategy, campaigns, messaging, tools, training, and commercialization efforts while communicating business priorities and market insights to key stakeholders.
  • Manage field marketing initiatives and commercial support activities, including sales enablement programs, Salesforce.com target management, funnel growth and pull-through activities, customer events, trade shows, and annual sales meetings.
  • Establish, monitor, and report key performance indicators, Salesforce metrics, forecasting measures, and return on investment analyses to evaluate program effectiveness, optimize investments, and support monthly and quarterly operating reviews.
  • Provide ongoing market intelligence and customer insights to improve commercial effectiveness, operational performance, customer experience, and understanding of customer buying behaviors while ensuring current and future solutions deliver compelling value for customers and the company.
  • Ensure all marketing programs, communications, and materials comply with corporate branding standards, legal requirements, regulatory guidelines, and company policies.
  • Lead or participate in strategic business development and targeted market development initiatives that support long-term growth objectives.
  • Provide updates on the business, demand plan, and forecast.
  • Travel up to 20%, including airplane, automobile, or train travel, with some overnight and global travel required.
Desired Qualifications
  • Experience in Diagnostics and/or Automation Marketing.
  • Proven hardware and software technical experience, including automation, clinical laboratory instrumentation, middleware, and laboratory information systems.
  • In-depth knowledge of hospital laboratory operations and understanding of customers and products.

About the company

QuidelOrtho provides in vitro diagnostics (IVD) products, including diagnostic tests and equipment that use immunoassay and molecular testing to detect medical conditions. Its products are used in point-of-care settings, clinical laboratories, and transfusion medicine, serving individual healthcare providers to large institutions. The company develops and manufactures these tests and devices, which run on specialized platforms or point-of-care instruments to analyze patient samples and deliver quick, accurate results. What sets QuidelOrtho apart is its long history and the combination of Quidel’s and Ortho’s expertise into a broad portfolio, with a global reach and long-term contracts with healthcare providers. The company’s goal is to improve diagnostic accuracy and efficiency to support better patient outcomes and broad access to essential diagnostic solutions.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

San Diego, California

Founded

1937

Get referred to QuidelOrtho

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • LEX launch later in 2026 adds a high-growth point-of-care molecular product.
  • Ex-China revenue grew 6% constant currency in Q2 2026, showing core franchise resilience.
  • Cost actions target $50 million net savings through 2027, supporting margin expansion.

What critics are saying

  • China's IVD pricing guidelines crushed Q2 2026 revenue 23.3% and guide cuts persist.
  • Free cash flow guidance was withdrawn after Q2 2026; deleveraging slips if China worsens.
  • A $2.8 billion debt load and B+ negative outlook leave bankruptcy risk if execution fails.

What makes QuidelOrtho unique

  • QuidelOrtho's LEX VELO, acquired April 2026, delivers PCR results in six minutes.
  • Its immunoassay, molecular, and transfusion platforms span point-of-care through hospital laboratories.
  • VITROS 450 and high-sensitivity troponin broaden a sticky installed base across care settings.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Employee Stock Purchase Plan

Paid Vacation

Paid Sick Leave

Paid Holidays

Employee Assistance Program

Wellness Program

Growth & Insights and Company News

Headcount

6 month growth

7%

1 year growth

7%

2 year growth

7%
PR Newswire
Oct 7th, 2026
QuidelOrtho appoints Sanjeev Sharma as VP of investor relations

QuidelOrtho Corporation has appointed Sanjeev Sharma as Vice President of Investor Relations, effective 28 September 2026. Sharma brings over 20 years of experience in investor relations, corporate strategy, and equity research. Most recently, he served as Senior Director of Investor Relations at Teva Pharmaceuticals. He previously spent more than a decade at Genpact in investor relations and business strategy roles, and nearly six years in sell-side equity research. Sharma holds a master's degree in finance and is a Chartered Financial Analyst. QuidelOrtho is a global provider of diagnostic solutions with expertise spanning clinical chemistry, immunoassay, immunohematology, and molecular testing.

Market Chameleon
Oct 7th, 2026
QuidelOrtho taps a 20-year IR veteran to lead shareholder communications.

QuidelOrtho taps a 20-year IR veteran to lead shareholder communications. 7 October 2026, 11:58 AM Leadership change centers on "sharpening communications" with a newly appointed VP of Investor Relations. QuidelOrtho Corporation (NASDAQ:QDEL) announced the appointment of Sanjeev Sharma, CFA, as Vice President, Investor Relations, effective September 28, 2026. The company said Sharma brings more than 20 years of experience spanning investor relations, corporate strategy, and equity research at global organizations. In the press release, Chief Financial Officer Micah Young highlighted Sharma's combination of investor relations leadership, healthcare experience, financial expertise, and capital markets perspective, describing it as especially valuable as QuidelOrtho works to "sharpen our communications and deepen our engagement with shareholders and analysts." Sharma's background blends healthcare IR and sell-side research experience. QuidelOrtho pointed to Sharma's most recent role as Senior Director of Investor Relations at Teva Pharmaceuticals, where he worked with senior leadership to communicate strategy and strengthen engagement with the investment community "during a period of significant transformation." Before Teva, he spent more than a decade at Genpact in progressively senior roles across investor relations and business strategy, and earlier in his career he spent nearly six years in sell-side equity research.

Spot On New Jersey
Oct 6th, 2026
Another biz flees Sherrill's New Jersey: QuidelOrtho plans 2027 closure of longtime Raritan facility.

Another biz flees Sherrill's New Jersey: QuidelOrtho plans 2027 closure of longtime Raritan facility. RARITAN, N.J. - Another longtime New Jersey business facility is heading for the exits. QuidelOrtho plans to close its 66-acre Route 202 campus in Raritan [...] |!| Raritan

Yahoo Finance
Aug 17th, 2026
QuidelOrtho rallies 31.7% despite China slowdown and slashed 2026 guidance

QuidelOrtho Corporation has risen 31.7% over three months, but faces headwinds that may limit further gains. The diagnostics company reported second-quarter revenues of $630.9 million, up 2.8% year over year, with Labs, Immunohematology and Point of Care segments all posting growth. Excluding China, revenues grew 6% at constant currency. Adjusted EBITDA increased 21% to $129 million, reaching a 20.5% margin, supported by ongoing cost optimisation efforts targeting $50 million in net savings through 2027. However, China revenues fell 23.3% at constant currency due to distributor inventory reductions ahead of pricing changes. Management expects these challenges to persist through 2026. QuidelOrtho lowered its full-year revenue guidance to $2.52-$2.60 billion from $2.70-$2.75 billion, and cut adjusted earnings guidance to 65-90 cents per share from $1.80-$2.00, citing China weakness and conservative respiratory season assumptions.

Yahoo Finance
Aug 17th, 2026
QuidelOrtho reports Q2 revenue of $630.9M, stock drops 12% on weak guidance

QuidelOrtho reported second-quarter revenues of $630.9 million, up 2.8% year-over-year and exceeding analyst expectations by 2.1%. The company, formed from the 2022 merger of Quidel and Ortho Clinical Diagnostics, develops diagnostic testing solutions for healthcare providers. Chief executive Brian Blaser noted strong performance across core franchises and regions, except China, where proposed IVD pricing guidelines and softer respiratory demand created headwinds. The broader healthcare equipment and supplies sector showed strength in Q2, with 36 tracked stocks beating revenue estimates by 2% on average. However, next quarter's guidance came in 1.7% below consensus. QuidelOrtho's shares fell 12.3% following its earnings announcement, which included weaker full-year guidance than peers. The stock currently trades at $14.31.